Xu et al., 2018. Hepatic pyroptosis in NASH Hepatic pyroptosis in NASH There is a clear need to identify molecular mechanisms of nonalcoholic steatohepatitis (NASH) to develop novel targeted therapies.… Click to show full abstract
Xu et al., 2018. Hepatic pyroptosis in NASH Hepatic pyroptosis in NASH There is a clear need to identify molecular mechanisms of nonalcoholic steatohepatitis (NASH) to develop novel targeted therapies. Pyroptosis is a highly inflammatory form of programmed cell death. Gasdermin D (GSDMD)-executed programmed necrosis is involved in inflammation and controls interleukin (IL)-1b release. In this issue of the Journal, Xu et al. studied its role in human and experimental NASH. GSDMD and its pyroptosisinducing fragment GSDMD-N were upregulated in liver tissues of human NASH and correlated with disease severity. Gsdmd / mice with experimental NASH exhibit decreased severity of steatosis and inflammation. GSDMD expression was associated with the secretion of pro-inflammatory cytokines and persistent activation of the NF-jB signaling pathway. Reduced steatosis in Gsdmd / mice was due to decreased expression of the lipogenic gene Srebp-1c and upregulated expression of lipolytic genes. This translational study reveals that GSDMD plays a key role as a pyroptosis executor in the pathogenesis of steatohepatitis by controlling cytokine secretion and lipogenesis.
               
Click one of the above tabs to view related content.